TY - JOUR T1 - In Vivo Evaluation of <sup>18</sup>F-MNI698: An <sup>18</sup>F-Labeled Radiotracer for Imaging of Serotonin 4 Receptors in Brain JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 858 LP - 864 DO - 10.2967/jnumed.113.132712 VL - 55 IS - 5 AU - Adriana Alexandre S. Tavares AU - Fabien Caillé AU - Olivier Barret AU - Caroline Papin AU - Hsiaoju Lee AU - Thomas J. Morley AU - Krista Fowles AU - Daniel Holden AU - John P. Seibyl AU - David Alagille AU - Gilles D. Tamagnan Y1 - 2014/05/01 UR - http://jnm.snmjournals.org/content/55/5/858.abstract N2 - Serotonin 4 receptors (5-hydroxytryptamine receptor 4 [5HT4R]) hold promise as a novel therapeutic approach to multiple brain disorders, including Alzheimer and Huntington disease. In vivo imaging of these receptors with selective 5HT4R radiotracers and PET would be valuable to investigate alterations in 5HT4R in different brain disorders and to assist drug discovery. In this study, 18F-MNI698 was evaluated as a potential PET radiotracer for imaging of 5HT4R in the brain. Methods: Eighteen PET studies were performed in 3 adult rhesus monkeys. The radiotracer was administered as a bolus intravenous injection or bolus plus constant infusion (time that would be required to inject the bolus at the infusion rate = 60 min), and arterial blood was collected for data quantification. Kinetic models were used to estimate distribution volumes and binding potentials, for which the cerebellum was used as a reference region. 18F-MNI698 test–retest variability and upper mass dose limits were determined. Preblocking studies using several doses of SB204070, a selective 5HT4R antagonist, were performed. Results: 18F-MNI698 avidly entered the monkey brain (peak percentage injected dose of ∼6.6%), and its brain distribution was consistent with known 5HT4R densities. At 120 min after bolus injection and after the start of radiotracer infusion, only less than 5% and approximately 10% parent compound was present in blood, respectively. Measured binding potentials were underestimated by 22%–36% when noninvasive methods were used for data quantification in comparison with invasive methods. A good agreement was found between test–retest measurements. The radiotracer upper mass dose limit (&lt;5% occupancy) was determined to be 13.1 μg per 70 kg of body weight. SB204070 blocked the radiotracer binding in a dose-dependent manner. Conclusion: Data indicate that 18F-MNI698 is a promising PET radiotracer for imaging of 5HT4R in the brain, and human studies are warranted based on these study results. ER -